Boston Scientific (BSX) Stock Forecast & Price Target

$86.70

+0.86 (+1.00%)

(As of 10/9/2024 ET)

Boston Scientific - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 20 Analyst Ratings

Sell
0

Hold
2

Buy
18

Based on 20 Wall Street analysts who have issued ratings for Boston Scientific in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 20 analysts, 2 have given a hold rating, 17 have given a buy rating, and 1 has given a strong buy rating for BSX.

Consensus Price Target

$87.60
1.04% Upside

According to the 20 analysts' twelve-month price targets for Boston Scientific, the average price target is $87.60. The highest price target for BSX is $95.00, while the lowest price target for BSX is $68.00. The average price target represents a forecasted upside of 1.04% from the current price of $86.70.

Get the Latest News and Ratings for BSX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Boston Scientific and its competitors.

BSX Analyst Ratings Over Time

Type	Current Forecast 10/10/23 to 10/9/24	1 Month Ago 9/10/23 to 9/9/24	3 Months Ago 7/12/23 to 7/11/24	1 Year Ago 10/10/22 to 10/10/23
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)
Buy	17 Buy rating(s)	18 Buy rating(s)	18 Buy rating(s)	15 Buy rating(s)
Hold	2 Hold rating(s)	2 Hold rating(s)	2 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$87.60	$85.38	$78.29	$60.10
Forecasted Upside	1.04% Upside	3.30% Upside	1.83% Upside	11.67% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Buy

Bigger Than Nvidia? (Ad)

Bigger Than Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the next Nvidia. Few in the media are talking about this story yet… but in the next 6 months that's all they'll talk about.

Go here now for this breaking story.

BSX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

BSX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Boston Scientific Stock vs. The Competition

Type	Boston Scientific	Medical Companies	S&P 500
Consensus Rating Score	2.95	2.79	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	1.47% Upside	11,088.45% Upside	7.37% Upside
News Sentiment Rating	Neutral News See Recent BSX News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Action	Rating	Price Target	Upside/Downside on Report Date
10/8/2024	Royal Bank of Canada 4 of 5 stars	Boost Target	Outperform ➝ Outperform	$85.00 ➝ $95.00	+10.65%
10/1/2024	Evercore ISI 2 of 5 stars	Boost Target	Outperform ➝ Outperform	$82.00 ➝ $90.00	+7.80%
9/4/2024	Raymond James 4 of 5 stars	Boost Target	Strong-Buy ➝ Strong-Buy	$91.00 ➝ $94.00	+15.85%
8/22/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$90.00 ➝ $92.00	+15.77%
8/22/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$78.00 ➝ $86.00	+8.08%
7/25/2024	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Hold ➝ Hold	$73.00 ➝ $78.00	+2.63%
Get the Latest News and Ratings for BSX and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Boston Scientific and its competitors with MarketBeat's FREE daily newsletter.
7/25/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$82.00 ➝ $85.00	+8.83%
7/25/2024	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$83.00 ➝ $88.00	+13.17%
7/25/2024	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$82.00 ➝ $86.00	+10.60%
7/25/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Outperform ➝ Outperform	$90.00 ➝ $91.00	+17.03%
7/16/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$77.00 ➝ $86.00	+10.16%
7/16/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$86.00 ➝ $90.00	+15.55%
7/15/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$79.00 ➝ $92.00	+17.86%
7/15/2024	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$80.00 ➝ $84.00	+7.61%
5/30/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$90.00	+20.05%
5/28/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$80.00 ➝ $95.00	+26.51%
5/15/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$85.00 ➝ $90.00	+22.50%
4/25/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$74.00 ➝ $90.00	+22.97%
4/25/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$72.00 ➝ $82.00	+11.58%
2/1/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Market Perform ➝ Market Perform	$58.00 ➝ $68.00	+5.44%
9/21/2023	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$58.00 ➝ $60.00	+10.91%
7/6/2023	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target		$58.00 ➝ $62.00	+16.43%
6/30/2023	22nd Century Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Initiates
6/30/2023	CL King Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$64.00	+20.10%
10/12/2022	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$50.00	+26.39%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 12:17 AM ET.

Should I Buy Boston Scientific Stock? BSX Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, October 1, 2024. Please send any questions or comments about these Boston Scientific pros and cons to contact@marketbeat.com.

Boston Scientific
Bull Case

Here are some ways that investors could benefit from investing in Boston Scientific Co.:

Boston Scientific Co. has shown consistent revenue growth over the past few quarters, indicating a strong financial performance.
The company's recent quarterly earnings report exceeded analysts' expectations, showcasing positive financial health.
With a diverse portfolio of medical devices for various specialties, Boston Scientific Co. has a broad market reach and potential for continued innovation.
Analysts have given Boston Scientific Co. a positive rating, with an average target price above the current stock price, suggesting potential for stock price appreciation.
Despite recent fluctuations, Boston Scientific Co.'s stock has shown resilience and maintained a relatively stable position in the market.

Boston Scientific
Bear Case

Investors should be bearish about investing in Boston Scientific Co. for these reasons:

While the company has shown growth, the medical devices industry is highly competitive, which may pose challenges for sustained growth.
Boston Scientific Co.'s stock price has experienced fluctuations, indicating potential volatility in the market.
There is a level of uncertainty in the healthcare sector, which could impact Boston Scientific Co.'s future performance and stock value.
Investing in medical device companies like Boston Scientific Co. carries inherent risks related to regulatory approvals and market acceptance of new products.
The company's debt-to-equity ratio is not negligible, which may raise concerns about financial leverage and stability in uncertain economic conditions.

BSX Forecast - Frequently Asked Questions

: According to the research reports of 20 Wall Street equities research analysts, the average twelve-month stock price forecast for Boston Scientific is $87.60, with a high forecast of $95.00 and a low forecast of $68.00.
: 20 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Boston Scientific in the last year. There are currently 2 hold ratings, 17 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" BSX shares.
: According to analysts, Boston Scientific's stock has a predicted upside of 1.04% based on their 12-month stock forecasts.
: Boston Scientific has been rated by research analysts at Barclays, BTIG Research, Canaccord Genuity Group, Citigroup, Deutsche Bank Aktiengesellschaft, Evercore ISI, JPMorgan Chase & Co., Morgan Stanley, Needham & Company LLC, Raymond James, Robert W. Baird, Royal Bank of Canada, TD Cowen, and Truist Financial in the past 90 days.
: Analysts like Boston Scientific more than other "medical" companies. The consensus rating score for Boston Scientific is 2.95 while the average consensus rating score for "medical" companies is 2.79. Learn more on how BSX compares to other companies.